Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has filed notice with NASDAQ of the Company's intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution at the Special Meeting of Stockholders of Merrimack scheduled to be held on Friday, May 10, 2024. Under the Plan of Dissolution, Merrimack intends to issue an initial liquidating cash dividend to its s.

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas. Merrimack's Board of Directors has evaluated the likelihood of receiving additional milestone payments under the I.

Merrimack Receives $225 Million Milestone Payment from Ipsen

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2023 Financial Results.

Merrimack Reports Full Year 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) reported that Ipsen, SA (“Ipsen”) issued a press release today announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma (mPDAC). Under the terms o.

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Third Quarter 2023 Financial Results.

Merrimack Reports Third Quarter 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2023 Financial Results.

Merrimack Reports Second Quarter 2023 Financial Results

NORTH ANDOVER, Mass.--(BUSINESS WIRE)--A newly released study shines a spotlight on a pressing crisis facing American education: Only 46% of current public K-12 educators would be “fairly” or “very likely” to advise their younger selves to choose teaching again and more than a third (35%) are considering leaving the profession altogether. This is according to the 2023 Merrimack College Teacher Survey, which was conducted by the Winston School of Education and Social Policy at Merrimack College,.

Merrimack College Teacher Survey Highlights Troubling K-12 Teacher Morale Issues

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023. “During the first quarter of 2023 our operating expenses remained consistent with prior quarters and were reduced both by proceeds we received from the receipt of an option fee paid in connection with the entry into an asset purchase option agreement on a preclinical asset and increased in.

Merrimack Reports First Quarter 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022. “We are encouraged by the results of the NAPOLI 3 trial as reported by Ipsen in November 2022 and the guidance that Ipsen has subsequently provided regarding its intention to file a supplemental New Drug Application with the U.S.

Merrimack Reports Full Year 2022 Financial Results

In December 2022, MACK got positive clinical results for its Phase III clinical trial of Onivyde in first line pancreatic cancer. A $225m milestone from Ipsen will be triggered on approval, which corresponds to about $16.75 per basic share.

Merrimack Still Has Significant Arbitrage Potential

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”), announced today that its Board of Directors (the “Board”) has extended the Section 382 net operating loss rights plan (the “Plan”) that was adopted in 2019. The Plan is designed to protect the Company's ability to use its valuable net operating loss (“NOL”) carryforwards and certain other valuable tax attributes.

Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

The stock price of Merrimack Pharmaceuticals (MACK) skyrocketed by over 240% today. This is why.

Merrimack Pharmaceuticals (MACK) Stock Skyrockets Over 240%: Details

Merrimack Pharmaceuticals (NASDAQ: MACK ) stock is rocketing higher on Wednesday following positive clinical trial data. Ipsen, Merrimack Pharmaceuticals' partner, reported that its Phase III NAPOLI 3 trial met its primary endpoint.

Why Is Merrimack Pharmaceuticals (MACK) Stock Up 220% Today?

Shares of Merrimack Pharmaceuticals Inc. MACK, +224.14% skyrocketed 199.5% toward a 4 1/2-year high in morning trading Wednesday, after the France-based biopharmaceutical company Ipsen IPSEY, +1.39% IPN, +3.85% said overnight that its Onivyde pancreatic cancer treatment met the primary endpoint of a Phase 3 trial. Ipsen said it plans to file a supplemental New Drug Application (NDA) with the U.S. Food and Drug Administration for Onivyde.

Merrimack stock rockets 200% after positive trial data on Onivyde pancreatic cancer treatment

Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Merrimack Reports Third Quarter 2022 Financial Results

MACK has a $225m milestone if its drug Onivyde works in first-line pancreatic cancer (already approved in second-line). The stock has been badly misvalued because the vast majority of pancreatic cancer drugs are targeted therapies that fail in the clinic.

Return Of The Mack: A Deeply Misunderstood Near-Term Readout

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2022 Financial Results

Merrimack Reports Second Quarter 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Provides Ipsen report of results from Phase III RESILIENT trial evaluating Onivyde® in second-line monotherapy for small cell lung cancer

Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 31, 2022. “During the first quarter of 2022 we continued to see reductions in our operating expenses and were able to close the sale of an additional preclinical asset” said Gary Crocker, Chairman of Merrimack's Board of Directors. “We continue to be focused on maintaining cash balances that will al

Merrimack Reports First Quarter 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2021 Financial Results

Merrimack Reports Full Year 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Reports Third Quarter 2021 Financial Results

Merrimack Reports Third Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended June 30, 2021. “We are pleased to report continued reductions in our operating expenses as well as positive overall cashflow during the quarter due to receipt of a tax refund,” said Gary Crocker, Chairman of Merrimack's Board of Directors. “Both Ipsen Pharmaceuticals and Elevation Oncology continue to repor

Merrimack Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2020 Financial Results

Merrimack Reports Full Year 2020 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Q3 2020 Earnings Release

News for Merrimack Pharmaceuticals Stock (MACK)